Clinical Trial Update: The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma [Phase 2]

View source ↗

Summary

Phase 2 trial update showing efficacy and safety data for anlotinib in patients with metastatic pheochromocytoma or paraganglioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma | Phase 2 | Status: COMPLETED